![DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-019-1785-7/MediaObjects/12967_2019_1785_Fig3_HTML.png)
DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text
Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g08.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts | Nature Communications Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-25122-4/MediaObjects/41467_2021_25122_Fig1_HTML.png)
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts | Nature Communications
![Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.onc.1205881/MediaObjects/41388_2002_Article_BF1205881_Fig1_HTML.jpg)
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patie
![Pharmaceutics | Free Full-Text | A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs Pharmaceutics | Free Full-Text | A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs](https://www.mdpi.com/pharmaceutics/pharmaceutics-11-00098/article_deploy/html/images/pharmaceutics-11-00098-g003.png)
Pharmaceutics | Free Full-Text | A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
![Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2455-2/MediaObjects/12885_2016_2455_Fig1_HTML.gif)
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig1/AS:618753171664896@1524533660240/Commonly-used-antitumor-efficacy-metrics-Top-panel-T-C-ratio-Middle-panel-TGI-Bottom_Q640.jpg)
Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram
![Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers](https://www.frontiersin.org/files/MyHome%20Article%20Library/793349/793349_Thumb_400.jpg)
Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers
![PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/321627338/figure/fig5/AS:583107354824705@1516035035014/PK-TGI-relationship-for-23a-in-Karpas-422-xenograft-model-A-tumor-growth-inhibition.png)
PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g06.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo | PLOS ONE
![PLS tumor growth inhibition coefficients (IC) 11 days after the start... | Download Scientific Diagram PLS tumor growth inhibition coefficients (IC) 11 days after the start... | Download Scientific Diagram](https://www.researchgate.net/publication/360996386/figure/fig2/AS:1169678474981378@1655884488476/PLS-tumor-growth-inhibition-coefficients-IC-11-days-after-the-start-of-treatment-and.png)
PLS tumor growth inhibition coefficients (IC) 11 days after the start... | Download Scientific Diagram
![JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors](https://df6sxcketz7bb.cloudfront.net/manuscripts/92000/92352/medium/jci.insight.92352.f2.jpg)
JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
![Characterization of tumor growth inhibition (TGI) data with the PK/PD... | Download Scientific Diagram Characterization of tumor growth inhibition (TGI) data with the PK/PD... | Download Scientific Diagram](https://www.researchgate.net/publication/233418620/figure/fig3/AS:333813650608131@1456598784909/Characterization-of-tumor-growth-inhibition-TGI-data-with-the-PK-PD-Model-a-TGI-data.png)